The global Rituxan market, valued at in 2025, is expected to decline steadily to by 2032, exhibiting a negative compound annual growth rate from 2025 to 2032. While Rituxan, a monoclonal antibody targeting CD20 proteins on B-cells, has transformed the treatment of autoimmune disorders and hematological malignancies like rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, the market is facing challenges. The expiration of patents and increasing competition from biosimilars are expected to significantly affect the market share of Rituxan during the forecast period.
The decline in Rituxan's market is primarily attributed to the rising competition from biosimilars, which offer more affordable alternatives. Despite the drug's successful use in chronic conditions, the high cost of treatment remains a key constraint. Additionally, the potential side effects of Rituxan and the growing number of treatment options are likely to limit its use. However, opportunities exist in expanding Rituxan's indications for diseases such as multiple sclerosis and other autoimmune disorders, alongside new formulations and delivery methods like subcutaneous administration, which could improve patient convenience and mitigate some of the market's challenges.
- This report provides in-depth analysis of the global Rituxan market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Rituxan market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key company covered as a part of this study include Genentech (Part of Roche), Biogen, Chugai Pharmaceutical Co., Ltd., and ZENYAKU KOGYO CO., LTD.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Rituxan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Rituxan market
-
- Non-Hodgkin’s Lymphoma (NHL)
- Mature B-cell Non-Hodgkin’s Lymphoma
- Mature B-cell Acute Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Rheumatoid Arthritis (RA)
- Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
- Pemphigus Vulgaris (PV)
-
- 100 mg/10 mL (single-use vial)
- 500 mg/50 mL (single-use vial)
-
- Pediatric
- Adult
- Geriatric
-
- Hospitals
- Oncology Centers
- Infusion Centers
- Ambulatory Surgical Centers
- Others (Specialty Clinics, etc.)
-
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Genentech (Part of Roche)
- Biogen
- Chugai Pharmaceutical Co., Ltd.
- ZENYAKU KOGYO CO., LTD
